iPSC 来源 CD19 CAR NK 细胞治疗复发/难治性淋巴瘤
iPSC-derived CD19 CAR NK cells for relapsed or refractory lymphoma.
肿瘤细胞治疗研究
ALL SOURCES
把在研试验和前沿论文合在一起看,按时间倒序排列。本页条数 = 前沿论文 + 临床试验两块之和(导航里的「临床试验」板块只收在招的那部分,不另计入)。
iPSC-derived CD19 CAR NK cells for relapsed or refractory lymphoma.
iPSC-derived NK cells with site-specific integration of CAR19 and IL24 at the multi-copy rDNA locus enhanced antitumor activity and proliferation.
Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma.
靶向 MUC1 的 CAR-NK 细胞对人 OTSCC 具有显著疗效,其令人期待的治疗反应值得进一步开展临床试验。
共 5 条
MEMBER ACCOUNT
登录成功会直接打开下一页。